TITLE

Review: Allergen-specific immunotherapies reduce symptoms, medication requirements, and bronchial hyperreactivity in asthma

AUTHOR(S)
Adelsberg, Bernard R.
PUB. DATE
July 2004
SOURCE
ACP Journal Club;Jul/Aug2004, Vol. 141 Issue 1, p18
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents the information that allergen-specific immunotherapies reduce symptoms, medication requirements, and bronchial hyperreactivity in asthma. Patients who received AS immunotherapy had greater symptomatic improvement, had reduced asthma medication requirements, and were less likely to develop increased nonspecific or AS BHR than those who received placebo. In patients with asthma, allergen-specific immunotherapies reduce asthma symptoms, medication requirements, allergen-specific bronchial hyperreactivity (BHR), and the development of increased nonspecific BHR.
ACCESSION #
13916262

 

Related Articles

  • Review: allergen specific immunotherapies reduce symptoms, medication requirements, and bronchial hyper-reactivity in asthma. Abramson, M. J.; Puy, R. M.; Weiner, J. M. // Evidence Based Medicine;Jul/Aug2004, Vol. 9 Issue 4, p114 

    The article presents a study on allergen specific (AS) immunotherapy for asthma. 75 randomised controlled trials met the selection criteria. Patients who received AS immunotherapy had greater symptomatic improvement, had reduced asthma medication requirements, and were less likely to develop...

  • Failure of sputum eosinophilia after eotaxin inhalation in asthma. Bumbocea, D.; Scheerens, J.; Mann, B. S.; Stirling, R. G.; Chung, K. F. // Thorax;May2004, Vol. 59 Issue 5, p372 

    Background: Eotaxin is a chemokine specific for eosinophils and may play an important role in eosinophil recruitment in asthma. The effects of eotaxin inhalation on sputum and blood eosinophils, exhaled nitric oxide (NO), and bronchial responsiveness were determined. Methods: Eotaxin was...

  • Analysis. Summerton, Nick // Update;5/19/2005, Vol. 70 Issue 5, p26 

    This article presents a study to find out whether intermittent as-needed corticosteroid treatment for mild persistent asthma equivalent to regular daily treatment. Treatment with daily or intermittent corticosteroid therapy in a six-centre randomised controlled trial was conducted. After...

  • Bronchial hyperreactivity in patients with allergic rhinitis: Forced expiratory flow between 25 and 75% of vital capacity might be a predictive factor. Ciprandi, Giorgio; Tosca, Maria Angela; Signori, Alessio; Cirillo, Ignazio // Allergy & Asthma Proceedings;Mar/Apr2011, Vol. 32 Issue 2, p4 

    Allergic rhinitis (AR) is considered a strong risk factor for the onset of asthma. Bronchial hyperreactivity (BHR) may be present in patients with AR. Forced expiratory flow between 25 and 75% of vital capacity (FEF25-75) may be impaired in AR patients. The aim of this study was to evaluate the...

  • Single inhaler maintenance and reliever therapy (SMART) in general practice asthma management: where are we? Thomas, Mike; Pavord, Ian // Primary Care Respiratory Journal;Mar2012, Vol. 21 Issue 1, p8 

    The author reflects on a study related to primary care which examined patients who have mild-to-moderate asthma. He notes that the study indicated that the change in bronchial hyperresponsiveness (BHR) was not different between the examined groups despite that fact that the Single Inhaler...

  • Chapter 9: Asthma classification. Koterba, Alan P.; Saltoun, Carol A. // Allergy & Asthma Proceedings;May/Jun2012 Supplement, Vol. 33, p28 

    Asthma is a chronic inflammatory disorder of the airways resulting physiologically in hyperreactivity and clinically in recurrent episodes of wheezing, chest tightness, or coughing. Airway inflammation, smooth muscle contraction, epithelial sloughing, mucous hypersecretion, bronchial...

  • The Potential of PDE4 Inhibitors in Respiratory Disease. Spina, Domenico // Current Drug Targets - Inflammation & Allergy;Sep2004, Vol. 3 Issue 3, p231 

    Glucocorticosteroids remain the gold standard therapy for the prophylactic treatment of asthma. Concerns regarding its long-term use particularly in young children has provided an impetus for discovering novel anti-inflammatory molecules with high tolerability and clinical efficacy. Whilst for...

  • Beclometasone.  // Reactions Weekly;3/25/2006, Issue 1094, p5 

    The article presents the case of a 31-year-old man who developed bronchospasm after inhaling beclometasone for allergic mild persistent asthma. The results of bronchial challenges undergone by the patient to identify the triggering agent are discussed. The link of contact between alcohol and the...

  • Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Verhoeven, G. T.; Hegmans, J. P. J. J.; Mulder, P. G. H.; Bogoard, I. M.; Hoogsteden, H. C.; Prins, J. -B. // Thorax;Aug2002, Vol. 57 Issue 8, p694 

    Background: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids does not appear to be as effective as similar treatment of asthma. It seems that only certain subgroups of patients with COPD benefit from steroid treatment. A study was undertaken to examine...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics